Results 321 to 330 of about 5,782,005 (384)

Tumour Cell Size Control and Its Impact on Tumour Cell Function

open access: yesCell Proliferation, EarlyView.
The regulatory mechanism of the size of tumour cells and its impact on the functions of tumour cells, as well as a summary of potential therapeutic targets for the corresponding mechanisms. ABSTRACT Cell size is an important component of cell morphological characteristics.
Min Zhou, Mei Zhou, Yang Jin
wiley   +1 more source

Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation. [PDF]

open access: yesCancer Immunol Immunother
Zheng D   +25 more
europepmc   +1 more source

LncRNA H19‐Encoded Micropeptide altH19 Promotes DNA Replication and Mitosis in Myeloma Cells by Enhancing the Phosphorylation of CDK2 at Threonine 160

open access: yesCell Proliferation, EarlyView.
The micropeptide altH19 interacts with phosphorylated CDK2 (p‐CDK2), subsequently activating CDK2 phosphorylation. This enhances the downstream E2F1 target gene RB activity, which accelerates DNA replication, ultimately leading to rapid myeloma cell mitosis and proliferation.
Yaxin Zhang   +6 more
wiley   +1 more source

Cyclophosphamide—A promising solution for refractory ICANS

open access: yes
British Journal of Haematology, EarlyView.
Manan Vora   +7 more
wiley   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

open access: yesCell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang   +18 more
wiley   +1 more source

Reversal of MPPa‐PDT Resistance in Osteosarcoma by Targeting ROCK2‐Mediated Autophagy

open access: yesCell Proliferation, EarlyView.
ROCK2 competes with MST1 to bind to the aa 28‐198 region of SAV1 and then regulates the Hippo pathway to affect autophagy, resulting in the resistance of OS to MPPa‐PDT. Targeted inhibition of ROCK2 by screening for J059‐0149 increases the sensitivity of osteosarcoma to MPPa‐PDT. ABSTRACT Osteosarcoma (OS) is a primary bone tumour that occurs mostly in
Xuan Yi   +14 more
wiley   +1 more source

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission).
Thomas Lund   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy